Publications by authors named "Zena Wilson"

Claim this Profile
T
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.
Elizabeth L Hardaker, Emilio Sanseviero, Ankur Karmokar, Devon Taylor, Marta Milo, Zena Wilson

Nat Commun· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relevance of ATM Status in Driving Sensitivity to DNA Damage Response Inhibitors in Patient-Derived Xenograft Models.
Ankur Karmokar, Rebecca Sargeant, Adina M Hughes, Hana Baakza, Zena Wilson

Cancers (Basel)· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to "Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models".
M Raymond V Finlay, Mark Anderton, Andrew Bailey, Scott Boyd, Joanna Brookfield, Zena Wilson

J Med Chem· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance.
Violeta Serra, Anderson T Wang, Marta Castroviejo-Bermejo, Urszula M Polanska, Marta Palafox, Zena Wilson

Clin Cancer Res· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors.
Anna D Staniszewska, Joshua Armenia, Matthew King, Chrysiis Michaloglou, Avinash Reddy, Zena Wilson

Oncoimmunology· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib.
Zena Wilson, Rajesh Odedra, Yann Wallez, Paul W G Wijnhoven, Adina M Hughes

Cancer Res· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells.
Rebecca L Lloyd, Paul W G Wijnhoven, Antonio Ramos-Montoya, Zena Wilson, Giuditta Illuzzi

Oncogene· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multi-batch design to deliver robust estimates of efficacy and reduce animal use - a syngeneic tumour case study.
Natasha A Karp, Zena Wilson, Eve Stalker, Lorraine Mooney, Stanley E Lazic

Sci Rep· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying strategies to target the metabolic flexibility of tumours.
Andrés Méndez-Lucas, Wei Lin, Paul C Driscoll, Nathalie Legrave, Laura Novellasdemunt, Zena Wilson

Nat Metab· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An innovative non-invasive technique for subcutaneous tumour measurements.
Juan Delgado-SanMartin, Beate Ehrhardt, Marcin Paczkowski, Sean Hackett, Andrew Smith, Zena Wilson

PLoS One· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress.
Lucy A Young, Lenka Oplustil O'Connor, Christelle de Renty, Margaret H Veldman-Jones, Thierry Dorval, Zena Wilson

Cancer Res· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models.
M Raymond V Finlay, Mark Anderton, Andrew Bailey, Scott Boyd, Joanna Brookfield, Zena Wilson

J Med Chem· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent.
Kevin M Foote, J Willem M Nissink, Thomas McGuire, Paul Turner, Sylvie Guichard, Zena Wilson

J Med Chem· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry.
Gemma N Jones, Claire Rooney, Nicola Griffin, Martine Roudier, Lucy A Young, Zena Wilson

Br J Cancer· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.
Hazel M Weir, Robert H Bradbury, Mandy Lawson, Alfred A Rabow, David Buttar, Zena Wilson

Cancer Res· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma.
Colin W Steele, Saadia A Karim, Joshua D G Leach, Peter Bailey, Rosanna Upstill-Goddard, Zena Wilson

Cancer Cell· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PDGFR Inhibition Results in Pericyte Depletion and Hemorrhage into the Corpus Luteum of the Rat Ovary.
Anthony P Hall, Susan Ashton, Judith Horner, Zena Wilson, Jaimini Reens

Toxicol Pathol· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.
Chris De Savi, Robert H Bradbury, Alfred A Rabow, Richard A Norman, Camila de Almeida, Zena Wilson

J Med Chem· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family.
Sandra R Brave, Kirsty Ratcliffe, Zena Wilson, Neil H James, Sue Ashton

Mol Cancer Ther· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation of MRI biomarkers with tumor necrosis in Hras5 tumor xenograft in athymic rats.
Daniel P Bradley, Jean J Tessier, Susan E Ashton, John C Waterton, Zena Wilson

Neoplasia· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis